-+ 0.00%
-+ 0.00%
-+ 0.00%

IMMUNEERING ANNOUNCES EXCEPTIONAL 64% OVERALL SURVIVAL AT 12 MONTHS IN FIRST-LINE PANCREATIC CANCER PATIENTS TREATED WITH ATEBIMETINIB + MGNP

Reuters·01/07/2026 21:00:00

Please log in to view news